Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
CA 2179015 C · Owner: University Of North Carolina At Chapel Hill · Inventors: Dykstra, Christine C.; Tidwell, Richard R.; Swanstrom, Ronald I.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is a method of inhibiting, retroviral integrase in a subject in need of such treatment. The method comprises administering to the subject an effective retroviral integrase inhibiting amount of a bis-benzimidazole compound such as bis 5amidino-2-benzimidazolyl methane, 1,2-bis 5-amidino-2benzimidazolyl ethane, 1, 2-bis 5-amidino-2benzimidazolyl ethene or a pharmaceutically acceptable salt thereof. A method for combatting retroviral infections is also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 18, 1995 and granted June 24, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 18, 2015.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 18, 2017.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.